Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

The iShares U.S. Pharmaceuticals ETF (IHE) was launched on 05/01/2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity ...

Apellis and Sobi have amended their partnership agreement for paroxysmal nocturnal hemoglobinuria (PNH) treatment Empaveli, ...

Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in ...

Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® ...

Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty ...

June 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO ... of royalties due to the Company from sales of BEYONTTRA in Europe to HealthCare Royalty (“HCRx”) and funds managed by Blue ...

Quantum BioPharma (NASDAQ: QNTM) , a biopharmaceutical company focused on innovative biotech assets, announced a non-brokered private placement of cl ...

Key considerations for discovery in AI-focused intellectual property (IP) litigation, including an examination of a ...

Gen Z billionaires are here! With some leading their companies while others pursue college degrees or quiet lives, these are ...

Quality information is even more important now in an age of AI slop where the information ecosystem is awash in misleading images and strange blah words that sound like they mean something but don’t ...

Apellis Pharmaceuticals ( NASDAQ: APLS) announced a new agreement with Sobi (SWOBF) ( OTCPK:SWOBY) involving a capped royalty ...